Orphan designation: Lactobacillus plantarum Treatment of amyotrophic lateral sclerosis, 16/12/2019 Withdrawn

Orphan designation: Alrefimotide acetate,riletamotide acetate,tapderimotide acetate Treatment of mesothelioma, 21/03/2024 Withdrawn

Orphan designation: Glofitamab Treatment of diffuse large B-cell lymphoma, 15/10/2021 Withdrawn

Human medicines European public assessment report (EPAR): Loqtorzi, Toripalimab, Date of authorisation: 19/09/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Kentera (previously Oxybutynin Nicobrand), oxybutynin, Date of authorisation: 15/06/2004, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Azilect, rasagiline, Date of authorisation: 21/02/2005, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Refixia, nonacog beta pegol, Date of authorisation: 02/06/2017, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Sugammadex Adroiq, sugammadex, Date of authorisation: 26/05/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Date of authorisation: 08/05/2017, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Ontozry, cenobamate, Date of authorisation: 26/03/2021, Revision: 10, Status: Authorised